Preliminary Results of a Retrospective Study on a Regimen Based on Orelabrutinib Combined with Anti-CD20 Monoclonal Antibody in Patients with Marginal Zone Lymphoma

被引：0
|
作者：
Peng, Hongling [1 ]
Xiang, Xixi [2 ]
Rao, Jun [2 ]
Yan, Wenzhe [1 ]
Cui, Yajuan [1 ]
Li, Ji [1 ]
Jiang, Yafeng [1 ]
Zhang, Xi [1 ,2 ]
机构：
[1] Cent South Univ, Xiangya Hosp 2, Dept Hematol, Changsha, Peoples R China
[2] Army Med Univ, Xinqiao Hosp, Med Ctr Hematol, State Key Lab Trauma & Chem Poisoning,Chongqing K, Chongqing, Peoples R China
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-203787
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6293 / 6293
页数：1
相关论文
共 50 条
  • [41] Clearing of risidual disease in patients with follicular lymphoma depends on the type of chemotherapy combined with the anti-CD20 monoclonal antibody (Rituximab) and the time point of therapy.
    Martin, S
    Kronenwett, R
    Free, M
    Mlynarczuk, I
    Feciskaninova, D
    Niederste-Hollenberg, A
    Meckenstock, G
    Haas, R
    BLOOD, 2001, 98 (11) : 135A - 136A
  • [42] A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial
    Grunenberg, Alexander
    Kaiser, Lisa M.
    Woelfle, Stephanie
    Schmelzle, Birgit
    Viardot, Andreas
    Moeller, Peter
    Barth, Thomas F. E.
    Muche, Rainer
    Dreyhaupt, Jens
    Raderer, Markus
    Kiesewetter, Barbara
    Buske, Christian
    BMC CANCER, 2021, 21 (01)
  • [43] Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
    Salles, Gilles
    Morschhauser, Franck
    Lamy, Thierry
    Milpied, Noel
    Thieblemont, Catherine
    Tilly, Herve
    Bieska, Gabi
    Asikanius, Elina
    Carlile, David
    Birkett, Joe
    Pisa, Pavel
    Cartron, Guillaume
    BLOOD, 2012, 119 (22) : 5126 - 5132
  • [44] Application of monoclonal anti-CD20 antibody rituximab in the treatment. of non-Hodgkin's lymphoma
    Mihaljevic, Biljana
    Jankovic, Snezana
    Jakovic, Ljubomir
    Jovanovic, Maja Perunicic
    Andelic, Bosko
    Milosevic, Violeta
    Sretenovic, Aleksandra
    Virijevic, Marjana
    Petrovic, Milan
    VOJNOSANITETSKI PREGLED, 2008, 65 (03) : 229 - 233
  • [45] Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma
    Heinzerling, L
    Dummer, R
    Kempf, W
    Schmid, MH
    Burg, G
    ARCHIVES OF DERMATOLOGY, 2000, 136 (03) : 374 - 378
  • [46] Orelabrutinib-Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Treatment of Marginal Zone Lymphoma: A Retrospective Study
    Li, He
    Liu, Jiazhuo
    Chen, Yuhui
    Tuohuti, Pazilaiti
    Wang, Yutong
    Tang, Xinzhu
    Xiang, Bing
    Jia, Yongqian
    Wu, Yu
    Tang, Yun
    Guo, Yong
    Wang, Jie
    Zheng, Yuhuan
    Liu, Yu
    Niu, Ting
    BLOOD, 2024, 144 : 6308 - 6309
  • [47] A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response
    Foran, JM
    Gupta, RK
    Cunningham, D
    Popescu, RA
    Goldstone, AH
    Sweetenham, JW
    Pettengell, R
    Johnson, PWM
    Bessell, E
    Hancock, B
    Summers, K
    Hughes, J
    Rohatiner, AZS
    Lister, TA
    BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (01) : 81 - 88
  • [48] Monoclonal anti-CD20 antibody rituximab (rituxan) for treatment of CD20-positive Hodgkin's lymphoma: The German experience.
    Rehwald, U
    Engert, A
    Diehl, V
    BLOOD, 2000, 96 (11) : 729A - 729A
  • [49] Combination monoclonal antibody therapy for lymphoma: Treatment with epratuzumab (anti-CD22) and rituximab (anti-CD20) is well tolerated.
    Leonard, JP
    Coleman, M
    Matthews, JC
    Fiore, JM
    Dosik, A
    Kapushoc, H
    Kin, E
    Cesano, A
    Wegener, WA
    Goldenberg, DM
    BLOOD, 2001, 98 (11) : 844A - 844A
  • [50] Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients
    Milpied, N
    Vasseur, B
    Parquet, N
    Garnier, JL
    Antoine, C
    Quartier, P
    Carret, AS
    Bouscary, D
    Faye, A
    Bourbigot, B
    Reguerre, Y
    Stoppa, AM
    Bourquard, P
    de Ligny, BH
    Dubief, F
    Mathieu-Boue, A
    Leblond, V
    ANNALS OF ONCOLOGY, 2000, 11 : 113 - 116
12345